Clinical Trial Update: A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating JCXH-105, an srRNA-based vaccine targeting herpes zoster (shingles), with the trial currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• JCXH-105

Snippet

Sponsor: Immorna Biotherapeutics, Inc. | Conditions: Herpes Zoster (HZ), Infectious Diseases | Phase 2 | Status: ACTIVE_NOT_RECRUITING